Search results
Results from the WOW.Com Content Network
Norovirus is surging across the U.S., with case numbers higher now than they've been at the same time in more than a decade, according to the U.S. Centers for Disease Control and Prevention (CDC ...
Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the winter vomiting bug, norovirus. The virus affects about four million ...
LigoCyte announced in 2007 that it was working on a vaccine and had started phase 1 trials. [66] The company has since been taken over by Takeda Pharmaceutical Company . [ 67 ] As of 2019 [update] , a bivalent (NoV GI.1/GII.4) intramuscular vaccine had completed phase 1 trials.
An ideal norovirus vaccine, Fink says, would not only cover at least 70% to 80% of currently circulating genotypes but also be versatile as genotypes evolve. Moderna is betting on mRNA technology ...
Vaxart has been progressing in the development of an oral tablet vaccine for Norovirus, the leading cause of acute gastroenteritis globally. Norovirus significantly impacts all age groups, particularly young children and the elderly, causing millions of cases annually with substantial healthcare and economic burdens.
Volunteers across the south of England are being recruited for a two-year norovirus vaccine trial.
ATC code J07 Vaccines is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup J07 is part of the anatomical group J Antiinfectives for systemic use. [4]
With norovirus accounting for around 12,000 hospital admissions every year, news that a groundbreaking vaccine trial is set to begin has raised hopes that it could eventually help to relieve the ...